AOD-9604 vs. Semaglutide: Different Mechanisms in Metabolic Research

Overview

AOD-9604 and Semaglutide are both studied in metabolic research contexts, but they operate through entirely different mechanisms and have very different evidence bases. This article compares the two compounds based on published research.

AOD-9604: GH Fragment with Lipolytic Activity

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 177–191 of human growth hormone, with an additional tyrosine residue at the N-terminus. It was originally developed by Metabolic Pharmaceuticals (Australia) as a potential obesity treatment based on the observation that the C-terminal fragment of GH retains lipolytic activity without the growth-promoting or diabetogenic effects of full-length GH.

Mechanism: AOD-9604 is believed to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat synthesis) through a mechanism that does not involve the GH receptor or IGF-1 pathway. The exact receptor target remains under investigation.

Published evidence: Animal studies in obese rodent models demonstrated significant reductions in body fat with AOD-9604 administration [1]. However, a Phase IIb clinical trial in obese adults (METAOD006) failed to demonstrate statistically significant weight loss compared to placebo [2]. AOD-9604 received GRAS (Generally Recognized as Safe) status from the FDA for use as a food ingredient, but it is not approved as a drug.

Semaglutide: GLP-1 Receptor Agonist

Semaglutide is a long-acting GLP-1 receptor agonist with 94% sequence homology to native GLP-1. It is FDA-approved as Ozempic (type 2 diabetes) and Wegovy (obesity) — making it one of the few compounds in this space with robust human clinical data.

Mechanism: Semaglutide activates GLP-1 receptors in pancreatic beta cells (promoting glucose-dependent insulin secretion), hypothalamic satiety centers (reducing appetite), and other tissues. Its extended half-life (~1 week) is achieved through albumin binding via fatty acid acylation.

Published evidence: The STEP clinical trial program demonstrated 14.9% mean body weight reduction over 68 weeks in adults with obesity [3]. The SELECT trial demonstrated cardiovascular risk reduction in adults with obesity and established cardiovascular disease [4].

Key Differences

| Parameter | AOD-9604 | Semaglutide | |---|---|---| | Mechanism | GH fragment, lipolytic | GLP-1 receptor agonist | | Human clinical data | Phase IIb (negative primary endpoint) | Phase III (robust positive data) | | FDA approval | GRAS (food ingredient only) | Approved drug (Ozempic, Wegovy) | | Research context | Lipolysis mechanisms | Metabolic/GLP-1 pathway research |

Research Applications

AOD-9604 is appropriate for research models studying the lipolytic mechanisms of GH fragments, or for studying fat metabolism pathways that are independent of the GH receptor.

Semaglutide is a well-validated research tool for studying GLP-1 receptor biology, appetite regulation, glucose metabolism, and cardiovascular effects. Its extensive clinical data provides a strong reference framework for preclinical research.

For research use only. Not for human or animal consumption. Semaglutide is an FDA-approved drug; research use should comply with applicable regulations.

References

1. Heffernan, M., et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182–5189.
2. Stier, H., et al. (2013). Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism, 3(1-2), 7–15.
3. Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002.
4. Lincoff, A.M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232.